IMNM
IMNM
NASDAQ · Biotechnology

Immunome Inc

$20.30
+0.09 (+0.45%)
As of Mar 25, 8:55 PM ET ·
Financial Highlights (FY 2026)
Revenue
17.76M
Net Income
-575,375,191
Gross Margin
Profit Margin
-3,240.4%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 51.0% 51.0% 51.0%
Operating Margin -3,382.4% -33.8% -27.1% -32.6%
Profit Margin -3,240.4% -28.7% -29.6% -28.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 17.76M 603.96M 550.96M 661.77M
Gross Profit 308.25M 281.20M 337.76M
Operating Income -600,667,545 -204,125,859 -149,200,100 -215,700,821
Net Income -575,375,191 -173,219,826 -162,867,502 -187,119,094
Gross Margin 51.0% 51.0% 51.0%
Operating Margin -3,382.4% -33.8% -27.1% -32.6%
Profit Margin -3,240.4% -28.7% -29.6% -28.3%
Rev Growth +13.0% +19.7% +11.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 349.67M 358.31M 392.24M
Total Equity 1.78B 1.86B 1.97B
D/E Ratio 0.20 0.19 0.20
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -597,510,321 -273,358,868 -247,027,649 -323,672,786
Free Cash Flow -130,399,233 -192,377,550 -194,010,121